Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Randomized, 2-Treatment, 2-Period, Crossover Study in Healthy Subjects to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule

NCT04768985 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04768985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04768985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Randomized, 2-Treatment, 2-Period, Crossover Study in Healthy Subjects to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
February 25, 2021
Completion date
May 10, 2021
Enrollment
66 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalence